These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28161110)

  • 21. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
    Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
    BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.
    El Miedany Y; El Gaafary M; Youssef S; Ahmed I; Bahlas S; Hegazi M; Nasr A
    Clin Rheumatol; 2016 Dec; 35(12):2915-2923. PubMed ID: 27658417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
    Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
    Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.
    Kuijper TM; Luime JJ; de Jong PH; Gerards AH; van Zeben D; Tchetverikov I; de Sonnaville PB; van Krugten MV; Grillet BA; Hazes JM; Weel AE
    Ann Rheum Dis; 2016 Dec; 75(12):2119-2123. PubMed ID: 27283332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
    Schett G; Emery P; Tanaka Y; Burmester G; Pisetsky DS; Naredo E; Fautrel B; van Vollenhoven R
    Ann Rheum Dis; 2016 Aug; 75(8):1428-37. PubMed ID: 27261493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study.
    Alperi-López M; Alonso-Castro S; Morante-Bolado I; Queiro-Silva R; Riestra-Noriega JL; Arboleya L; Ballina-García FJ
    Reumatol Clin (Engl Ed); 2020; 16(5 Pt 1):319-323. PubMed ID: 30318269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].
    Pattloch D; Richter A; Manger B; Dockhorn R; Meier L; Tony HP; Zink A; Strangfeld A
    Z Rheumatol; 2017 Apr; 76(3):210-218. PubMed ID: 27518855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Perspective of ultrasound-guided strategy to reduce/discontinue biologics].
    Ikeda K; Iwamoto T; Nakajima H
    Nihon Rinsho; 2016 Jun; 74(6):919-23. PubMed ID: 27311179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.
    Terslev L; Brahe CH; Hetland ML; Georgiadis S; Ellegaard K; Juul L; Huynh T; Døhn UM; Fana V; Møller T; Krabbe S; Ørnbjerg LM; Glinatsi D; Røgind H; Hansen A; Nørregaard J; Jacobsen S; Jensen DV; Manilo N; Asmussen K; Boesen M; Rastiemadabadi Z; Morsel-Carlsen L; Møller JM; Krogh NS; Østergaard M
    Rheumatology (Oxford); 2021 Dec; 60(12):5549-5559. PubMed ID: 33748831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing down and then discontinuing biologic therapy in rheumatoid arthritis: a review of the literature.
    Chen DY; Lau CS; Elzorkany B; Hsu PN; Praprotnik S; Vasilescu R; Marshall L; Llamado L
    Int J Rheum Dis; 2018 Feb; 21(2):362-372. PubMed ID: 29205904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany.
    Krause D; Krause C; Rudolf H; Baraliakos X; Braun J; Schmitz E
    Clin Rheumatol; 2021 Mar; 40(3):887-893. PubMed ID: 32822057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of relapse after discontinuation of biologic agents by ultrasonographic assessment in patients with rheumatoid arthritis in clinical remission: high predictive values of total gray-scale and power Doppler scores that represent residual synovial inflammation before discontinuation.
    Iwamoto T; Ikeda K; Hosokawa J; Yamagata M; Tanaka S; Norimoto A; Sanayama Y; Nakagomi D; Takahashi K; Hirose K; Sugiyama T; Sueishi M; Nakajima H
    Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1576-81. PubMed ID: 24515410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tapering Biologic Therapy for Rheumatoid Arthritis: A Qualitative Study of Patient Perspectives.
    Chan SJ; Stamp LK; Liebergreen N; Ndukwe H; Marra C; Treharne GJ
    Patient; 2020 Apr; 13(2):225-234. PubMed ID: 31802391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Birkner B; Rech J; Stargardt T
    PLoS One; 2020; 15(1):e0226754. PubMed ID: 31895926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
    Lampropoulos CE; Orfanos P; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2017; 35(2):192-200. PubMed ID: 28094760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Discontinuation of immunosuppressive and immunomodulatory drugs in connective tissue diseases].
    Targońska-Stępniak B
    Wiad Lek; 2015; 68(3):265-70. PubMed ID: 26753211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized rheumatic medicine through dose reduction reduces the cost of biological treatment - a retrospective intervention analysis.
    Meyer MK; Andersen M; Ring T; Andersen GN; Ehlers LH; Rasmussen C; Stensballe A
    Scand J Rheumatol; 2019 Sep; 48(5):398-407. PubMed ID: 31322029
    [No Abstract]   [Full Text] [Related]  

  • 38. Key findings from studies of methotrexate tapering and withdrawal in rheumatoid arthritis.
    Subesinghe S; Scott IC
    Expert Rev Clin Pharmacol; 2015; 8(6):751-60. PubMed ID: 26289226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
    Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
    Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.
    Alivernini S; Peluso G; Fedele AL; Tolusso B; Gremese E; Ferraccioli G
    Arthritis Res Ther; 2016 Feb; 18():39. PubMed ID: 26842890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.